What is the recommended management for mitotane-associated colitis?

Management of Mitotane-Associated Colitis

The primary management of mitotane-associated colitis requires immediate discontinuation or dose reduction of mitotane, followed by treatment with corticosteroids (prednisolone 40 mg daily for moderate cases or methylprednisolone 1-2 mg/kg/day IV for severe cases), with escalation to biologic agents (infliximab or vedolizumab) if there is inadequate response to steroids within 3 days.

Initial Assessment and Severity Grading

When mitotane-associated colitis is suspected, you must first:

• Confirm colitis via sigmoidoscopy or colonoscopy with biopsy to exclude infectious causes (though treatment should not be delayed for microbiology results)
• Grade severity based on stool frequency, blood in stool, systemic symptoms, and endoscopic findings
• Monitor vital signs, stool frequency, C-reactive protein, and obtain plain abdominal radiography to identify those requiring urgent intervention

The evidence shows mitotane causes gastrointestinal toxicity in virtually all patients 1, with 34.6% experiencing more than 6 adverse events 1. Diarrhea and gastrointestinal symptoms are among the most common adverse effects 2.

Treatment Algorithm by Severity

Mild to Moderate Disease (Grade 1-2)

• Consider dose reduction or temporary hold of mitotane while assessing risk-benefit ratio 3
• Initiate oral mesalazine 2-4 g daily or balsalazide 6.75 g daily as first-line therapy 4
• Add topical mesalazine 1 g daily (suppositories for distal disease, enemas for more proximal involvement) for additional benefit 4
• Monitor closely with repeat assessment in 3-5 days

Moderate Disease Not Responding to Mesalazine

• Start oral prednisolone 40 mg daily 4
• Continue mitotane hold until symptoms improve to grade 1
• Taper prednisolone gradually over 8 weeks once symptoms improve; more rapid reduction risks early relapse 4
• Maintain hydrocortisone replacement at 80-100 mg/day due to mitotane's enzymatic activity 3

Severe Disease (Grade 3-4)

• Permanently discontinue mitotane for grade 4 or strongly consider discontinuation for grade 3 5
• Hospitalize for IV therapy if dehydration, electrolyte imbalance, or severe symptoms present 4
• Administer IV methylprednisolone 1-2 mg/kg/day until symptoms improve to grade 1 5
• Consider early introduction of infliximab or vedolizumab if:
  • High-risk endoscopic features on initial examination
  • Inadequate response to steroids after 3 days 5
  • Colonic dilatation (transverse colon >5.5 cm) 4

Steroid-Refractory Disease

• Add infliximab or vedolizumab as biologics of choice 5
• Consider repeat colonoscopy to reassess disease activity and exclude complications 5
• Alternative agents for refractory cases include:
  • Fecal microbiota transplant
  • JAK inhibitor tofacitinib
  • IL-12 blocking antibody ustekinumab 5

Critical Management Considerations

Supportive care is essential throughout:

• IV fluid and electrolyte replacement to correct dehydration
• Blood transfusion to maintain hemoglobin >10 g/dL
• Subcutaneous heparin to reduce thromboembolism risk 4
• Nutritional support (enteral or parenteral) if malnourished 4
• Maintain adequate glucocorticoid replacement (hydrocortisone 80-100 mg/day) given mitotane's adrenolytic effects 3

Common Pitfalls to Avoid

1. Do not delay corticosteroid treatment while awaiting stool cultures in severe cases 4
2. Do not use infliximab if concurrent hepatic toxicity is present; choose alternative immunosuppressants like mycophenolate 5
3. Do not rapidly taper steroids (faster than 8 weeks) as this increases relapse risk 4
4. Do not restart mitotane until colitis is in complete remission and only after careful risk-benefit assessment 5
5. Monitor for colonic dilatation with daily abdominal radiography if initial films show dilation or if clinical deterioration occurs 4

Resumption of Mitotane Therapy

Given that mitotane is the cornerstone of adrenocortical carcinoma treatment 3, 6, the decision to resume therapy must balance:

• Tumor stage and recurrence risk (high-risk patients with stage III, R1 resection, or Ki-67 >10% have greatest need) 6
• Severity of colitis episode (grade 3-4 should not be rechallenged)
• Achievement of endoscopic and histologic remission 5
• Alternative treatment options for the underlying malignancy

If resumption is considered, start at lower doses with intensive monitoring every 2-4 weeks for gastrointestinal symptoms 7.